ABCL (AbCellera Biologics) GF Value Rank: 3 (As of Jul. 03, 2026) — 200% Above Median


ABCL AbCellera Biologics Inc ABCL
56 GF Score
Price $8.11
GF Value $5.51
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is AbCellera Biologics GF Value Rank?

AbCellera Biologics ABCL +6.78% 56 GF Value Rank is 3 as of Jul. 03, 2026, which is 200% above its 10-year median of 1.00. GuruFocus rates ABCL with a GF Score™ of 56/100 and a GF Value™ of $5.51 (Significantly Overvalued). The stock has 5 warning signs investors should review.

AbCellera Biologics has the GF Value Rank of 3.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


AbCellera Biologics GF Value Rank Related Terms


ABCL vs AGIO, KOD, IMNM: GF Value Rank Comparison

For the Biotechnology subindustry, AbCellera Biologics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbCellera Biologics GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's GF Value Rank falls into.


ABCL
56GF Score
AbCellera Biologics Inc ABCL
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 3 mean?
AbCellera Biologics (ABCL) has a GF Value Rank of 3 as of Jul. 03, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on AbCellera Biologics and its competitors. This is 200% above median its historical median of 1.00. Over the past decade, AbCellera Biologics' GF Value Rank has ranged from 1.00 to 10.00.
Is AbCellera Biologics' GF Value Rank too high?
AbCellera Biologics' current GF Value Rank of 3 is 200% above median its 10-year median of 1.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, AbCellera Biologics has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' GF Value Rank compare to AGIO and KOD?
AbCellera Biologics' GF Value Rank of 3 can be compared against companies in the Biotechnology industry. Historically, AbCellera Biologics' own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on AbCellera Biologics and its competitors. AbCellera Biologics's current GF Value Rank is 3, which is 200% above median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.51, compared to a current price of $8.11 — trading 47.2% above its estimated fair value. The current GF Value Rank is 3, which is 200% above median its 10-year median of 1.00. AbCellera Biologics' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current GF Value Rank is 3 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbCellera Biologics (ABCL) Overvalued in 2026?

Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued. The current stock price of $8.11 is trading 47.2% above its estimated GF Value™ of $5.51. GuruFocus considers AbCellera Biologics to be Significantly Overvalued.

Key valuation signals for ABCL:

  • GF Value Rank: 3 (200% above median its 10-year median of 1.00)
  • GF Value™: $5.51 vs. price of $8.11 (47.2% above fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AbCellera Biologics Business Description

Other Exchanges 8QQ:Germany
Address 150 W 4th Avenue, Vancouver, BC, CAN, V5Y 1G6
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
56GF Score

Get the complete analysis for ABCL

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.11
Price
$5.51
GF Value